PBM

NASDAQ Healthcare

Psyence Biomedical Ltd. - Ordinary Shares

Biotechnology

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

�� 市场数据

价格	$7.60
成交量	49,050,620
市值	17.43M
贝塔系数	0.310
RSI（14日）	94.7 超买
200日均线	$86.24
50日均线	$2.78
52周最高	$468.36
52周最低	$1.92
Price / Book	0.19